LevelBlue Completes Acquisition of Aon’s Cybersecurity and IP Litigation Consulting Groups
1.8.2025 14:00:00 CEST | Business Wire | Press release
Strategic deal enhances LevelBlue's cybersecurity offerings, solidifying its position as the world’s largest leading independent, pure-play MSSP
LevelBlue, a global leader in cloud-based, AI-driven managed security services, today announced the completion of its acquisition of Aon’s (NYSE: AON) Cybersecurity and Intellectual Property (IP) Litigation consulting groups, including the renowned cybersecurity firm, Stroz Friedberg, and Elysium Digital. With this completion the consulting group will operate as Stroz Friedberg, a LevelBlue company.
This strategic acquisition adds elite cyber and high-tech IP litigation consulting expertise to the LevelBlue portfolio, which includes a globally recognized platform of approximately 300 technology professionals with deep relationships across Fortune 500 companies, 80 percent of the Am Law 100, and most of the UK’s top 20 law firms. As a result, LevelBlue will significantly fortify its incident response and advisory capabilities, while expanding its footprint within the legal sector.
LevelBlue is also redefining cybersecurity by integrating Stroz Friedberg’s expert consulting with its 24/7 managed detection and response (MDR) services. LevelBlue's MDR offerings will benefit from real-time threat data coming from incident response team engagements, using machine learning to continuously feed new threat indicators, while helping auto-detect and auto-respond to threats. This unified, AI-driven approach enhances the company’s ability to protect against digital threats and quickly manage incidents. These integrated capabilities position LevelBlue as the largest global independent pure-play Managed Security Services Provider (MSSP).
“The close of this acquisition enables LevelBlue to deliver an unmatched breadth of cybersecurity services and expertise to customers on a global scale,” said Robert McCullen, Chairman and CEO of LevelBlue. “Capitalizing on the Stroz Friedberg consulting expertise along with our AI-driven managed security services, we are empowering organizations to proactively manage digital risk and respond to incidents with greater speed and precision. Our combined strengths will set a new standard for cyber resilience in the industry.”
With the close of this transaction, Aon and LevelBlue will work collaboratively to deliver comprehensive cybersecurity solutions to clients.
“Cybersecurity challenges are becoming increasingly complex and urgent for our clients, demanding more integrated and adaptive solutions,” said Christian Hoffman, Global Specialty & Financial Products Leader at Aon. “Aon will continue to deliver leading cyber brokerage capabilities through our Cyber Solutions group, CyQu platform and Cyber Risk Analyzer, while deepening our collaboration with providers like LevelBlue to enhance our clients’ protection and resilience in an evolving threat landscape.”
Santander served as financial advisor and Kirkland & Ellis LLP served as legal advisor to LevelBlue. Lazard served as financial advisor and Latham & Watkins LLP served as legal advisor to Aon.
In addition to this deal, LevelBlue recently announced an agreement to acquire Trustwave, a global provider of cybersecurity and MDR services from the MC2 Security Fund (MC2). Together, these acquisitions further solidify LevelBlue’s position as the largest, independent pure-play MSSP in the industry.
For more information on LevelBlue and its managed security, consulting, and threat intelligence services, please visit www.levelblue.com.
About LevelBlue
We simplify cybersecurity through award-winning managed services, experienced strategic consulting, threat intelligence, and renowned research. Our team is a seamless extension of yours, providing transparency and visibility into security posture and continuously working to strengthen it.
We harness security data from numerous sources and enrich it with artificial intelligence to deliver real-time threat intelligence; this enables more accurate and precise decision making. With a large, always-on global presence, LevelBlue sets the standard for cybersecurity today and tomorrow. We easily and effectively manage risk, so you can focus on your business.
About Aon
Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.
Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon’s newsroom and sign up for news alerts here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250801890991/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom